Skip to content
Logo Mablink
Menu
  • About us
    • Our Vision
    • Leadership team
    • Investors
  • Technology
    • About ADC
    • PSARlinkTM
  • Pipeline
  • Partnering
  • Newsroom

News

Home  >  News
News

Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners

The financing will enable the company to advance its lead candidate to the clinic and to build a pipeline of next-generation antibody-drug conjugates (ADCs) Its proprietary ADC technology opens the …

News

Mablink Bioscience announces appointment of its Head of Preclinical Research and Development

Mablink Bioscience appoints Dr. Lenka Kyrych Sadilkova as its Head of Preclinical Research and Development to support the development of its pipeline of ADC candidates using its proprietary PSARlink™ linker …

News

Mablink Bioscience announces appointment of its Chief Development Officer

Mablink Bioscience appoints its Chief Development Officer to support the regulatory development of its lead candidate MBK-103, an ADC using its proprietary PSARlink™ linker Lyon, France, March 1, 2022 Mablink …

News / Partnerships

Mablink Bioscience and Emergence Therapeutics Enter into a Licensing Agreement to Develop Antibody Drug Conjugate as a potential cancer therapy

Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s proprietary PSARlink™ drug-linker technology Lyon, France & Duisburg, Germany, October 21, 2021 Mablink Bioscience S.A.S. a …

News

Mablink Bioscience, the next generation ADC company, raises €4 Million from a syndicate of private investors

Mablink Bioscience to move forward its ADC pipeline targeted at cancers with high unmet medical needs Lyon, France, April 27, 2021 Mablink Bioscience, a company developing the next generation of …

News / Press

La presse quotidienne nationale s’empare du thème “ADC”

Le quotidien “Le Figaro” s’est fait l’écho de l’engouement de l’industrie pharmaceutique pour l’approche ADC (anticorps conjugués) dans un article publié le 3 mars : lien vers l’article. Mablink est …

Edouard Leroy, C.B.D.O.
News

Edouard Leroy joins as Chief Business Development Officer

We are pleased to announce a strategic addition to Mablink’s team with the arrival of Edouard Leroy as our Chief Business Development Officer. 

Mr Guillaume Gerard & Mr. Jean-Guillaume Lafay
News / Partnerships

Mablink adopts Agatha Software solutions

Mablink is adopting Agatha’s solution, a global leader in quality and content management solutions for life sciences.

More information

  • Contact
  • Careers
  • Legal Notice (FR)
  • Privacy policy (FR)
  • Credits
Keep in touch
Copyright © 2023 Mablink Bioscience